Why Walgreens Q1 Is Underwhelming

Photo of Chris Lange
By Chris Lange Updated Published
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.
Why Walgreens Q1 Is Underwhelming

© Justin Sullivan / Getty Images

Walgreens Boots Alliance Inc. (NASDAQ: WBA | WBA Price Prediction) reported its fiscal first-quarter financial results before the markets opened on Wednesday. The retailer said that it had $1.37 in earnings per share (EPS) and $34.3 billion in revenue, which compared with consensus estimates of $1.41 in EPS and $34.6 billion in revenue. The same period of last year reportedly had $1.46 in EPS and $33.79 billion in revenue.

Overall, net sales saw an increase of 1.6% from the year-ago quarter and an increase of 2.3% on a constant currency basis.

The Retail Pharmacy USA segment had fourth-quarter sales of $26.1 billion, an increase of 1.6% year over year. At the same time, Retail Pharmacy International saw sales of $2.7 billion, a decrease of 5.4%.

Pharmaceutical Wholesale had fourth-quarter sales of $6.0 billion, an increase of 5.2%. On a constant currency basis, comparable sales increased 8.3%, led by emerging markets and the United Kingdom.

The company maintained guidance of roughly flat growth in fiscal 2020 adjusted EPS at constant currency rates, with a range of plus or minus 3%. Consensus estimates are calling for $5.93 in EPS and $139.91 billion in revenue for the full year.

[nativounit]

Stefano Pessina, executive vice chair and chief executive, commented:

We are maintaining our outlook for the year despite a soft first quarter. We are confident our strategic plans are the right ones to drive long-term sustainable growth going forward. In addition, during the quarter we were very satisfied with the progress made in our Transformational Cost Management Program and with the strong cash flow we delivered.

Shares of Walgreens traded down nearly 6% at $55.99 on Wednesday, in a 52-week range of $49.03 to $74.94. The consensus price target is $57.21.

[recirclink id=606035]
[wallst_email_signup]

Photo of Chris Lange
About the Author Chris Lange →

Chris Lange is a writer for 24/7 Wall St., based in Houston. He has covered financial markets over the past decade with an emphasis on healthcare, tech, and IPOs. During this time, he has published thousands of articles with insightful analysis across these complex fields. Currently, Lange's focus is on military and geopolitical topics.

Lange's work has been quoted or mentioned in Forbes, The New York Times, Business Insider, USA Today, MSN, Yahoo, The Verge, Vice, The Intelligencer, Quartz, Nasdaq, The Motley Fool, Fox Business, International Business Times, The Street, Seeking Alpha, Barron’s, Benzinga, and many other major publications.

A graduate of Southwestern University in Georgetown, Texas, Lange majored in business with a particular focus on investments. He has previous experience in the banking industry and startups.

Featured Reads

Our top personal finance-related articles today. Your wallet will thank you later.

Continue Reading

Top Gaining Stocks

CBOE Vol: 1,568,143
PSKY Vol: 12,285,993
STX Vol: 7,378,346
ORCL Vol: 26,317,675
DDOG Vol: 6,247,779

Top Losing Stocks

LKQ
LKQ Vol: 4,367,433
CLX Vol: 13,260,523
SYK Vol: 4,519,455
MHK Vol: 1,859,865
AMGN Vol: 3,818,618